)
Visual
test
Cipher Pharmaceuticals
Cipher Pharmaceuticals (CPH) investor relations material
Cipher Pharmaceuticals Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary7 Nov, 2025
Executive summary
Achieved strong growth in Q3 2025, with revenue up 24% year-over-year to $12.8 million, driven by U.S. Natroba sales and Canadian portfolio gains.
Natroba sales reached $8.1 million in Q3 2025, up 4% sequentially, and contributed $22.5 million year-to-date.
Adjusted EBITDA rose 79% to $7.3 million in Q3 2025, with net income increasing to $5.5 million from $0.3 million in Q3 2024.
Significant debt reduction, with $17 million repaid in Q3 and $32 million year-to-date, lowering the revolving credit facility to $8 million.
Recent acquisition of Natroba in July 2024 expanded the U.S. dermatology platform and offers market share growth opportunities.
Financial highlights
Q3 2025 net revenue was $12.8 million, up 24% year-over-year; year-to-date revenue reached $38.2 million, up 78%.
Canadian product portfolio revenue grew 5% in Q3 and 18% year-to-date.
Licensing revenue declined 28% in Q3 and 44% year-to-date, mainly due to lower Absorica and Lipofen royalties.
Adjusted EBITDA for Q3 and year-to-date was $7.3 million and $21.1 million, up 79% and 97% year-over-year.
Gross margin was 82% in Q3 2025, up from 81% in Q3 2024.
Outlook and guidance
Direct-to-consumer sales model for Natroba to launch in early 2026, aiming to drive further U.S. growth.
Plans to launch Natroba in Canada, with a new drug submission to Health Canada in Q4 2025.
Outlicensing opportunities for Natroba being explored globally, with focus on Europe and Japan.
Actively pursuing complementary product in-licensing and acquisition opportunities aligned with U.S. operations.
Substantial liquidity for growth, with $82 million USD growth capital available and low leverage profile.
How many states are considering Natroba as preferred?
Post-debt, what is the capital allocation plan?
How is Natroba's resistance advantage leveraged?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026. - 6 FebARI
Proposed $9B real estate loan portfolio acquisition highlights disciplined, long-term strategy. - 6 FebSMCI
Q2 revenue jumped 123% to $12.7B, with FY26 guidance raised to at least $40B. - 6 FebRJF
Record revenues and assets, higher dividend, and acquisitions despite lower net income. - 6 FebFFIE
Raising capital for global EV and AI expansion, with regulatory and dilution risks highlighted.
Next Cipher Pharmaceuticals earnings date
Q4 202519 Mar, 2026
Cipher Pharmaceuticals
Next Cipher Pharmaceuticals earnings date
Q4 202519 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company focused on dermatology. It acquires, develops, and markets prescription products for skin-related conditions through in-licensed and proprietary therapies. The company is headquartered in Mississauga, Canada, and its shares are listed on the TSX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage